JAZZ - Neena M Patil Implements A Sell Strategy: Offloads $548K In Jazz Pharmaceuticals Stock | Benzinga
On May 7, a recent SEC filing unveiled that Neena M Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals (NASDAQ:JAZZ) made an insider sell.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday outlined that Patil executed a sale of 5,000 shares of Jazz Pharmaceuticals with a total value of $548,250.
During Wednesday's morning session, Jazz Pharmaceuticals shares down by 0.0%, currently priced at $111.21.
Get to Know Jazz Pharmaceuticals Better
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals's Financial Performance
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 1.03%. This indicates a substantial increase in the company's top-line earnings. In comparison to its ...